top of page

Dr Sara Prickett

(BSc, PhD)

Chief Scientific Officer

Sara Prickett has over 15 years’ research experience in cellular immunology and was responsible for the preclinical development of Aravax's peanut allergy therapy. Prior to Aravax, Dr Prickett held senior research posts at Alfred Health and Monash University where she played a major role in the research underpinning the peanut allergy therapy being developed by Aravax. She is a co-inventor, and co-founder of the company.


Dr Prickett received her Bachelor of Science from Sheffield University and PhD from Imperial College, London. 

bottom of page